First Tracks Biotherapeutics Inc

EcoR1 Capital’s first‑day purchase of First Tracks Biotherapeutics shares signals strong confidence in its antibody platform, bolstering stability and future growth potential.

First Tracks insider buying shows senior execs’ confidence in the biopharma’s pipeline and long‑term growth, yet investors should watch upcoming vestings and dilution.